IP Library Granted Patent US 7,115,274
Granted Patent B2
US 7,115,274 · App. 11/040,419 · Granted Oct 3, 2006

Method of using autologous fibroblasts to promote healing of wounds and fistulas

Assignee: Isolagen Technologies, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,115,274
App. No.
11/040,419
Granted
Oct 3, 2006
Kind
B2
Abstract

The present invention provides a method of using autologous fibroblasts to promote wound or fistula healing in an animal.

Claims (24)

1. A method of promoting healing of a fistula in an animal, wherein said fistula has a fistula tract opening and is susceptible to healing upon administration of autologous fibroblasts, which method comprises:

(a) obtaining autologous fibroblasts, and

(b) administering the autologous fibroblasts in the form of an injection into the fistula tract opening, wherein the said autologous fibroblasts promote healing of the fistula.

2. The method of claim 1 , wherein said animal is a human.

3. The method of claim 1 , wherein said autologous fibroblasts are derived from a tissue which is the same type of tissue as a tissue in which the fistula exists.

4. The method of claim 1 , wherein said fibroblasts are cultured in the animal's own serum.

5. The method of claim 1 , wherein said fibroblasts are passaged in culture less than about ten times.

6. The method of claim 5 , wherein said fibroblasts are passaged in culture from about four to about six times.

7. The method of claim 1 , wherein about 20 million autologous fibroblasts are administered per administration.

8. The method of claim 1 , wherein said fistula is an iatrogenic fistula.

9. The method of claim 1 , wherein said fistula is a spontaneous fistula.

10. The method of claim 9 , wherein said fistula is due to infection.

11. The method of claim 9 , wherein the said fistula is due to inflammation.

12. The method of claim 9 , wherein said fistula is due to ischaemia.

13. The method of claim 9 , wherein said fistula is due to carcinoma.

14. The method of claim 9 , wherein said fistula is due to radiation.

15. The method of claim 9 , wherein said fistula is an enterocutaneous fistula.

16. The method of claim 15 , wherein said fistula is a gastric, duodenal, pancreatic, jejunal, ileal, or colonic fistula.

17. The method of claim 1 , wherein said fistula is a tracheo-esophageal fistula.

18. The method of claim 1 , wherein said fistula is a tracheocutaneous fistula.

19. The method of claim 1 , wherein said fistula is an esophagocutaneous fistula.

20. The method of claim 1 , wherein said fistula is a bronchopleural fistula.

21. The method of claim 1 , wherein said fistula is an anal fistula.

22. The method of claim 1 , wherein said autologous fibroblasts are administered by injection of the external fistula tract opening and internal endoscopic injection.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2021
From: FIBROCELL TECHNOLOGIES, INC.
To: FIBROCELL SCIENCE, INC.
Reel/Frame 055641/0367 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2021
From: FIBROCELL SCIENCE, INC.
To: CASTLE CREEK BIOSCIENCES, LLC
Reel/Frame 055642/0372 →
CHANGE OF NAME Recorded Oct 3, 2011
From: ISOLOGEN TECHNOLOGIES, INC.
To: FIBROCELL TECHNOLOGIES, INC.
Reel/Frame 027008/0939 →
CHANGE OF NAME Recorded Jul 15, 2011
From: ISOLAGEN, INC.
To: FIBROCELL SCIENCE, INC.
Reel/Frame 026601/0287 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2007
From: KELLER, GREGORY S.
To: ISOLAGEN TECHNOLOGIES, INC.
Reel/Frame 019501/0975 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2007
From: REVAZOVA, ELENA
To: KELLER, GREGORY S.
Reel/Frame 019501/0979 →
Continuity (3)
Division 0998015000
Provisional Application 6013645700 · May 28, 1999
Related Publication 20050147596A1 · Jul 7, 2005